Intralesional bleomycin injections in the treatment of benign lymphoepithelial cysts of the parotid gland in HIV-positive patients: Case reports

Authors

  • Glen M. Monama MBChB, MMed (ORL),

    Corresponding author
    1. Department of Otorhinolaryngology, University of Pretoria, Steve Biko Academic, Gauteng, South Africa
    • Senior Consultant, Department of Otorhinolaryngology, University of Pretoria and Kalafong Hospital, Private Bag X169, Pretoria 0001, South Africa
    Search for more papers by this author
  • Mashudu I. Tshifularo MBChB, MMed

    1. Department of Otorhinolaryngology, University of Pretoria, Kalafong Hospital, Gauteng, South Africa
    Search for more papers by this author

  • The authors have no vested interest in bleomycin, do not stand to benefit from the sale of this product, and have not been funded by any of the companies producing the product.

Abstract

Benign lymphoepithelial cysts (BLCs) of the parotid gland are associated with human immunodeficiency virus. These cysts may grow large and uncomfortable, causing significant cosmetic embarrassment for the patient. Several treatment options have been described with varying successes. We report successful treatment of three adults with bleomycin. All three patients presented with bilateral parotid enlargements. They received a total dose of between 180 U and 270 U of bleomycin over a period of 6 to 10 weeks. They all responded completely without morbidity or recurrence. Bleomycin is effective in the treatment of BLCs of the parotid glands in HIV-positive patients. Laryngoscope, 2010

Ancillary